文献速递乳腺癌放疗

化生性乳腺癌的治愈性治疗策略:回顾性队列结局综述

Curative Approaches for Metaplastic Breast Cancer: A Retrospective Cohort Outcome Review.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-06-29

该研究基于新加坡健康服务联合乳腺癌登记库2001年1月至2020年8月的170例化生性乳腺癌或基质产生癌患者,分析其病理临床特征、新辅助化疗反应及生存结局。多因素分析显示辅助放疗显著改善总生存和无病生存,风险比分别为0.29(95%CI 0.13-0.62,P<.005)和0.23(95%CI 0.10-0.50,P<.005)。

要点

  • 辅助放疗与总生存(HR 0.29)和无病生存(HR 0.23)显著改善相关。
  • 临床T3/T4期及淋巴结受累与不良结局相关。
  • 新辅助化疗后疾病稳定与较差的总生存和无病生存相关。

核心结论

  • 辅助放疗在改善化生性乳腺癌患者结局中起关键作用。
  • 尽管取得进展,仍存在挑战,需要继续研究以优化新辅助化疗策略并深入探讨影响治疗反应的细微因素。

研究设计与样本

  • 基于登记库的回顾性队列研究,纳入2001年1月至2020年8月新加坡健康服务联合乳腺癌登记库中年龄≥21岁、诊断为化生性乳腺癌或基质产生癌的女性,共170例。

主要发现

  • 87.1%为非转移性疾病,12.9%为转移性疾病;诊断时年龄范围46至65岁(中位56岁)。
  • 队列主要特征为三阴性乳腺癌(64%)、晚期临床分期(77.6%)、淋巴结阴性(67.6%)和3级疾病(74.1%)。
  • 接受以治愈为目的的新辅助化疗的患者(17.6%)中,病理完全缓解率为19.2%,疾病进展率为46.2%。
  • 多因素分析显示辅助放疗显著改善总生存和无病生存,风险比分别为0.29(95%CI 0.13-0.62,P<.005)和0.23(95%CI 0.10-0.50,P<.005)。
  • 临床T3和T4期及淋巴结受累与不良结局相关;新辅助化疗后疾病稳定与较差的总生存和无病生存相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metaplastic breast cancer (MBC) is a rare and heterogeneous breast cancer subtype, and there are critical gaps in our understanding of its long-term outcomes. This retrospective cohort study aimed to address these gaps by scrutinizing the pathologic and clinical aspects of MBC to enhance clinical decision-making and refine patient care strategies. METHODS AND MATERIALS: This registry-based retrospective cohort study included women aged ≥21 years diagnosed with MBC or matrix-producing carcinoma. The data were obtained from January 2001 to August 2020 from the Joint Breast Cancer Registry of Singapore Health Services, which included 23,935 patients. Demographic and clinicopathologic characteristics, neoadjuvant chemotherapy responses, and survival outcomes were analyzed. Statistical assessments involved univariate and multivariate Cox proportional hazards models and Kaplan-Meier survival analyses. RESULTS: This study enrolled 170 patients; 87.1% had non-metastatic disease, and 12.9% had metastatic disease. The age of patients at diagnosis ranged from 46 to 65 years (median, 56 years). The cohort's predominant characteristics were triple negative breast cancer (64%), advanced clinical stage (77.6%), node negativity (67.6%), and grade 3 disease (74.1%). In patients receiving neoadjuvant chemotherapy with curative intent treatment (17.6%), neoadjuvant chemotherapy yielded a pathologic complete response of 19.2% and a disease progression rate of 46.2%. Multivariate analysis showed that adjuvant radiation therapy significantly improved overall survival and disease-free survival, with hazard ratios of 0.29 (95% CI, 0.13-0.62; P < .005) and 0.23 (95% CI, 0.10-0.50; P < .005), respectively. Clinical T3 and T4 stages and nodal involvement were associated with poor outcomes. Stable disease after neoadjuvant chemotherapy was associated with poor overall survival and disease-free survival. CONCLUSIONS: This study sheds light on the complex landscape of MBC and emphasizes the pivotal role of adjuvant radiation therapy in enhancing patient outcomes. Despite advancements, challenges persist that warrant continued research to refine neoadjuvant chemotherapy strategies and delve into the nuanced factors that influence treatment responses.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yit LFN, Quek ZHS, Tan TJ, et al. Curative Approaches for Metaplastic Breast Cancer: A Retrospective Cohort Outcome Review. Int J Radiat Oncol Biol Phys. 2024. PMID: 38950711. doi:10.1016/j.ijrobp.2024.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。